MEMPHIS, Tenn--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced it has entered into a development agreement with OsteoGenix Incorporated, a privately-held orthobiologic pharmaceutical company based in California. The agreement will enable OsteoGenix to complete preclinical work on its proprietary bone anabolic agent and advance this program through clinical trials. The agreement will give Medtronic an additional source of bone growth therapies for surgeons whose patients require bone grafting options.
